Last May, people were thrilled to learn that a 7-month-old baby who became the first in the world to receive a personalized ...

Immunovant remains a high-risk, high-reward play, hinging on the success of its next-gen candidate IMVT-1402. Click to read my latest analysis of IMVT stock.

A machine learning model using basic clinical data can predict PH risk, identifying key predictors like low hemoglobin and elevated NT-proBNP. Researchers have developed a machine learning model that ...

Thermo Fisher Scientific is breaking out the big bills to score a clinical research treat. With $8.875 billion in cash, the ...

A new tool at its Tisch Cancer Center helps improve accuracy, efficiency and patient access by streamlining information from the Epic EHR to clinical trial platforms.

NYU Langone’s Center for Multisite Studies is led by experts who are experienced in managing and supporting research.

Cecilia Bahit, MD, and Carolyn Lam, MBBS, PhD, FACC, discuss the barriers patients face when seeking access to clinical trial ...

Tiziana Life Sciences is a buy due to its platform optionality and upcoming catalysts that outweigh its dilution risk and ...

Cabaletta Bio Inc. (NASDAQ: CABA) is one of the best stocks under $3 to invest in. On October 27, Cabaletta Bio announced ...

Acquisition is expected to strengthens Thermo Fisher’s position in delivering clinical information to pharma and biotech ...

Autolus Therapeutics plc (NASDAQ: AUTL) is one of the best stocks under $5 with highest upside potential. Autolus ...